AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23656463
Drug: Casein supplement
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein supplement diet (Casein Group, CG; n = 68)
Trial: 19622007
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + colesevelam HCl
Trial: 19622007
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + matching placebo
Trial: 17597499
Drug: Ganoderma lucidum
RxNorm normalized name: GANODERMA LUCIDUM STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganoderma lucidum extract (2 grams, twice daily for 10 days)
Trial: 15080351
Drug: 10% povidone-iodine
RxNorm normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% povidone-iodine solution applied 3 times at 2-month intervals (N = 13)
Trial: 15080351
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group, N = 12)
Trial: 9895085
Drug: Sameridine 0.73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sameridine 0.73 mg/kg (S-Large)
Trial: 9895085
Drug: Sameridine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sameridine 0.15 mg/kg (S-Small)
Trial: 9895085
Drug: Morphine 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.10 mg/kg
Trial: 3710663
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g daily for 3 weeks)
Trial: 10389804
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 10 mg
Trial: 29413502
Drug: Lebrikizumab 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 125 mg subcutaneously (SC)
Trial: 29413502
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg orally
Trial: 26771423
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate (500 mg/d)
Trial: 26771423
Drug: Calcium Phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Phosphate (500 mg/d)
Trial: 17922130
Drug: Triadcortyl (TAC)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triadcortyl (TAC) ointment
Trial: 17922130
Drug: 10% glycerine-ichthammol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycerine-ichthammol (GI) solution
Trial: 3113778
Drug: TRH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH infusion (5 micrograms/min)
Trial: 3113778
Drug: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME)
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms) after TRH infusion
Trial: 3113778
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with DAMME bolus
Trial: 3113778
Drug: TRH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH infusion alone
Trial: 3113778
Drug: TRH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH infusion with DAMME bolus
Trial: 22515556
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily maintenance dose)
Trial: 22515556
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose)
Trial: 19812099
Drug: Clinical pathways
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pathways (CP) for hospital treatment of HF
Trial: 16333533
Drug: 2x treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x treatment
Trial: 9352604
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of rhenium-186
Trial: 9352604
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of rhenium-186 in combination with triamcinolone hexacetonide
Trial: 9352604
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of triamcinolone hexacetonide alone
Trial: 8239200
Drug: Albumin replacement
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin replacement to a level greater than or equal to 3.5 g/dL (AR group)
Trial: 10365287
Drug: Inogatran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (all doses)
Trial: 7497776
Drug: Dopexamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (1 mg.kg‐1.min‐1)
Trial: 7497776
Drug: Dopamine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2.5 mg.kg‐1.min‐1)
Trial: 1674295
Drug: Desferrioxamine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months)
Trial: 1674295
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (lecithin)
Trial: 7178257
Drug: Daily exposures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposures to hot and humid conditions (D: 43 degrees C, 32 Torr, 165 min)
Trial: 21899583
Drug: Probiotical (synbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotical (synbiotic food supplement)
Trial: 15134183
Drug: Indinavir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 600 mg + Ritonavir 100 mg twice daily
Trial: 15134183
Drug: Indinavir 400
RxNorm normalized name: indinavir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 400 mg + Ritonavir 100 mg twice daily
Trial: 9254875
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (monophasic in 9 patients, biphasic in 5 patients)
Trial: 9254875
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (biphasic)
Trial: 8015885
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid (50 mg, 3.7 +/- 0.9 mg/kg)
Trial: 8015885
Drug: Acetaminophen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (100 mg, 7.7 +/- 1.7 mg/kg)
Trial: 3619710
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol (160 mg/d)
Trial: 3619710
Drug: Primidone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primidone (250 mg at night)
Trial: 3619710
Drug: Clonazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (4 mg/d)
Trial: 23832723
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus Simvastatin (combination group)
Trial: 18208570
Drug: interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interferon alfa-2a (3 million units three times weekly)
Trial: 25725564
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid (ITS) initial treatment (ITSi)
Trial: 25725564
Drug: Intratympanic salvage
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic salvage treatment (ITSs)
Trial: 16847412
Drug: Uridine-enriched food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine-enriched food supplement NucleomaxX
Trial: 14657844
Drug: Topical calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcineurin inhibitors
Trial: 14657844
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy and early intervention
Trial: 11464618
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Helicobacter pylori infection
Trial: 30547305
Drug: High-flexion TKA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flexion TKA implant
Trial: 29763676
Drug: Real dual-tDCS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real dual-tDCS (anodal over the lesioned hemisphere, cathodal over the non-lesioned hemisphere) at 2-mA intensity for 20 minutes followed by conventional physical therapy
Trial: 29763676
Drug: Sham dual-tDCS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dual-tDCS followed by conventional physical therapy
Trial: 29763676
Drug: Real dual-tDCS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real dual-tDCS and conventional physical therapy
Trial: 24662947
Drug: E10A plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10A plus chemotherapy (cisplatin and paclitaxel)
Trial: 22664749
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 600 mg
Trial: 22664749
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 1800 mg
Trial: 22664749
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 2400 mg
Trial: 17549429
Drug: Medication (MED)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (MED) (oxybutynin ER)
Trial: 9797978
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment combining two therapies
Trial: 9797978
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment designed to mimic experimental treatment
Trial: 8106774
Drug: GenHevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenHevac B vaccine (G), 20 micrograms/dose
Trial: 8106774
Drug: Hevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac B vaccine (H), 5 micrograms/dose
Trial: 8106774
Drug: GenHevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenHevac B vaccine (G), after booster at month 12
Trial: 8106774
Drug: Hevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac B vaccine (H), after booster at month 12
Trial: 2698453
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fluspirilene
Trial: 2698453
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg fluspirilene
Trial: 2698453
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg fluspirilene
Trial: 4549500
Drug: Monovalent acetone‐inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent acetone‐inactivated typhoid vaccine by jet injection
Trial: 4549500
Drug: Heat‐killed TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat‐killed TAB by jet injection
Trial: 4549500
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (monovalent acetone‐inactivated typhoid vaccine and heat‐killed TAB)
Trial: 4549500
Drug: Second jet
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second jet injection 5 weeks after the first
Trial: 29231496
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with auricular point sticking therapy
Trial: 29231496
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (20 mg paroxetine hydrochloride once a day for 8 weeks)
Trial: 24590412
Drug: Family-centered, school-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-centered, school-based intervention including a 13-week behavioral parenting intervention and concurrent group for children.
Trial: 21365053
Drug: Prosthetic abutments
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosthetic abutments with a Morse taper connection and a platform switch (test group)
Trial: 12640530
Drug: 48-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 24 weeks)
Trial: 12640530
Drug: 72-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 48 weeks)
Trial: 10598606
Drug: Succinylcholine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1.0 mg/kg)
Trial: 10553857
Drug: Mivacurium (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.20 mg/kg)
Trial: 2877594
Drug: Vecuronium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.08 mg/kg)
Trial: 27332391
Drug: Daily teleconsultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily teleconsultation for one week between hospital-based telenurses and patients with severe COPD
Trial: 22336194
Drug: Preventative physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventative physiotherapy program, carried out twice a day for three weeks (week 34, 35, 36 postmenstrual age).
Trial: 7940651
Drug: Zung-12 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zung-12 administered in the morning
Trial: 7940651
Drug: Zung-12 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zung-12 administered in the afternoon
Trial: 2573679
Drug: Hyperbaric oxygen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen, hypoxic cell radiosensitizers, modification of the oxygen‐unloading capacity of haemoglobin, hyperthermia, bio‐reductive drugs
Trial: 2573679
Drug: Hypoxic cell
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic cell radiosensitizers and other agents
Trial: 31669562
Drug: Clonidine 50
RxNorm normalized name: cloNIDine 500 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 50 μg
Trial: 31669562
Drug: Clonidine 100
RxNorm normalized name: cloNIDine 100 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 100 μg
Trial: 12380661
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (50-100 microg/h)
Trial: 19441968
Drug: Filial Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filial Therapy and Kinder Training (play-based interventions)
Trial: 17868732
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg daily for 4 weeks, followed by 2 weeks off drug per treatment cycle)
Trial: 11584378
Drug: Triple-antigen recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antigen recombinant vaccine (20-microg dose)
Trial: 11584378
Drug: Single-antigen vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-antigen vaccine (S only)
Trial: 7864561
Drug: Naftidrofuryl (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (400 mg, 2 daily infusions for 8 days)
Trial: 31978354
Drug: IIV (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV (full human dose, intramuscular)
Trial: 30232107
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who understood their treatment intent
Trial: 30232107
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who did not understand their treatment intent
Trial: 27871601
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.1 mL/kg)
Trial: 20931097
Drug: Men (perceived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men (perceived benefit from CC)
Trial: 20931097
Drug: Women (perceived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women (perceived benefit from CC)
Trial: 20931097
Drug: Low-risk men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk men (perceived benefit from CC)
Trial: 20931097
Drug: Low-risk women
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk women (perceived benefit from CC)
Trial: 20931097
Drug: Low-risk younger
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk younger patients (perceived benefit from CC)
Trial: 20931097
Drug: Low-risk older
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk older patients (perceived benefit from CC)
Trial: 20931097
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who agreed to CC (perceived benefit from CC)
Trial: 20931097
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were disagreeable or made no comment (perceived benefit from CC)
Trial: 18230968
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Trial: 18230968
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (100 g/day for 2 weeks)
Trial: 18230968
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (100 g/day for 2 weeks)
Trial: 18230968
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (200 g/day for 2 weeks)
Trial: 18230968
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (200 g/day for 2 weeks)
Trial: 18230968
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Trial: 18230968
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Trial: 2515825
Drug: acebutolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol (10 mg/kg)
Trial: 758131
Drug: Propylthiouracil (PTU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU; 300 mg/day)
Trial: 31860742
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene or scaling and root planning ± placebo or polyunsaturated fatty acids fish oil
Trial: 28321995
Drug: 4% Garcinia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Garcinia mangostana L. pericarp gel (MGA) as local drug delivery with scaling and root planing (SRP)
Trial: 25787121
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel with scaling and root planing (SRP)
Trial: 25795452
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg QD)
Trial: 25795452
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg QD)
Trial: 23442248
Drug: Live vaccine
RxNorm normalized name: rubella virus live vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live vaccine as the most recent vaccination
Trial: 23442248
Drug: Inactivated vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccine as the most recent vaccination
Trial: 16427389
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 microg/kg
Trial: 11574493
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/day for three months
Trial: 9762741
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine medial branch injections